Prochlorperazine maleate 25 mg Oral Tablet
RxNorm 198366
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 198366 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: prochlorperazine maleate 25 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCD
Semantic Clinical Drug (SCD):
Prochlorperazine 25 mg Oral Tablet
(Atom ID: 12324270)
SY
Synonym (SY):
Prochlorperazine (as prochlorperazine maleate) 25 mg Oral Tablet
(Atom ID: 3273402)
PSN
Prescribable Name (PSN):
Prochlorperazine maleate 25 mg Oral Tablet
(Atom ID: 6368235)
PT
Designated preferred name (PT):
Prochlorperazine maleate 25 mg oral tablet
(Atom ID: 9252969)
FN
Full form of descriptor (FN):
Product containing precisely prochlorperazine maleate 25 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10316537)
Patient Education
Prochlorperazine
Prochlorperazine suppositories and tablets are used to control severe nausea and vomiting. Prochlorperazine tablets are also used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Prochlorperazine tablets are also used on a short-term basis to treat anxiety that could not be controlled by other medications. Prochlorperazine should not be used to treat any condition in children who are younger than 2 years old or who weigh less than 20 pounds (about 9 kilograms). Prochlorperazine is in a class of medications called conventional antipsychotics. It works by decreasing abnormal excitement in the brain.
[Learn More]
* Please review the disclaimer below.